{"classes":[{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation was not calculable due to n=1.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Day 1 Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"66","value":"153"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Day 1 Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nIcrucumab: 12 mg/kg IV on day 1 and Day 8 of each 21-day cycle","id":"OG000","title":"Docetaxel + Icrucumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of study drug and had evaluable PK data for Icrucumab and there was no PK data for Docetaxel arm.","reportingStatus":"POSTED","timeFrame":"Cycle 2:Predose,1hr post-EOI;Cycle 3:Predose,EOI,1.5hr,24hr,48hr,72hr,168hr Post EOI","title":"PK: Cmin Icrucumab","type":"SECONDARY","unitOfMeasure":"ug/mL"}